콘텐츠로 건너뛰기
Merck
모든 사진(1)

문서

N-004

Supelco

Naloxone solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

로그인조직 및 계약 가격 보기


About This Item

실험식(Hill 표기법):
C19H21NO4
CAS Number:
Molecular Weight:
327.37
EC Number:
MDL number:
UNSPSC 코드:
41116107
PubChem Substance ID:
NACRES:
NA.24

Grade

certified reference material

형태

liquid

특징

Snap-N-Spike®/Snap-N-Shoot®

포장

ampule of 1 mL

제조업체/상표

Cerilliant®

농도

1.0 mg/mL in methanol

기술

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

응용 분야

forensics and toxicology

형식

single component solution

저장 온도

2-8°C

SMILES string

Oc1ccc2C[C@H]3N(CC[C@@]45[C@@H](Oc1c24)C(=O)CC[C@@]35O)CC=C

InChI

1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1

InChI key

UZHSEJADLWPNLE-GRGSLBFTSA-N

유전자 정보

유사한 제품을 찾으십니까? 방문 제품 비교 안내

일반 설명

Naloxone is an opiate drug used to counter the effects of opioid overdose. This certified solution standard is applicable for use in LC/MS or GC/MS applications such as clinical toxicology and forensic analysis. Naloxone is sold under the trade names Narcan®, Nalone, and Narcan®ti.

법적 정보

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Narcan is a registered trademark of Endo Pharmaceuticals Inc.
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

픽토그램

FlameSkull and crossbonesHealth hazard

신호어

Danger

유해 및 위험 성명서

Hazard Classifications

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

표적 기관

Eyes,Central nervous system

Storage Class Code

3 - Flammable liquids

WGK

WGK 2

Flash Point (°F)

49.5 °F - closed cup

Flash Point (°C)

9.7 °C - closed cup


시험 성적서(COA)

제품의 로트/배치 번호를 입력하여 시험 성적서(COA)을 검색하십시오. 로트 및 배치 번호는 제품 라벨에 있는 ‘로트’ 또는 ‘배치’라는 용어 뒤에서 찾을 수 있습니다.

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

이미 열람한 고객

Jason Boland et al.
Clinical medicine (London, England), 13(2), 149-151 (2013-05-18)
Opioids can induce respiratory depression by invoking a centrally mediated decrease in involuntary respiratory rate, which in severe cases can cause a decrease in oxygen saturation. If respiratory depression is opioid induced, both low respiratory rate and low oxygen saturation
Anne M Neumann et al.
Journal of addictive diseases, 32(1), 68-78 (2013-03-14)
Patients with opioid addiction who receive prescription opioids for treatment of nonmalignant chronic pain present a therapeutic challenge. Fifty-four participants with chronic pain and opioid addiction were randomized to receive methadone or buprenorphine/naloxone. At the 6-month follow-up examination, 26 (48.1%)
R Terry Furst
Journal of addictive diseases, 32(1), 53-67 (2013-03-14)
This study explores strategies that Suboxone misusers utilize while in drug treatment. Ethnographic interviews were conducted with 14 patients who had cycled in and out of Suboxone treatment. The objective of the study is to identify strategies implemented by patients
Robert Taylor et al.
Expert opinion on investigational drugs, 22(4), 517-525 (2013-03-15)
Opioid receptor antagonists are well known for their ability to attenuate or reverse the effects of opioid agonists. This property has made them useful in mitigating opioid side effects, overdose and abuse. Paradoxically, opioid antagonists have been reported to produce
The opioid system is involved in the analgesic effects of Tactivin.
A N Inozemtsev et al.
Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections, 450, 130-133 (2013-07-04)

문서

Although both biphenyl and phenyl-hexyl phases can resolve these compounds, the former exhibits excellent peak shape and substantially less silanol-derived ion exchange activity.

자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..

고객지원팀으로 연락바랍니다.